The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a fundamental mediator in patients whose hypertension is difficult-to-control.Hypertension remains a major global health issue, and the number one modifiable risk factor of early morbidity/mortality. Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025Idorsia Ltd (SIX: IDIA) announces that its novel dual endoth ...